(Q45857827)

17 December 2017

title

Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade (English)

1 reference

17 December 2017

0 references

1 reference

6

L Puig

1 reference

17 December 2017

author name string

S Sauleda

1

1 reference

17 December 2017

M Martorell

2

1 reference

17 December 2017

J I Esteban

3

1 reference

17 December 2017

C Tural

4

1 reference

17 December 2017

I Ruiz

5

1 reference

17 December 2017

R Esteban

7

1 reference

17 December 2017

J Guardia

8

1 reference

17 December 2017

V Vargas

9

1 reference

17 December 2017

publication date

1 May 2006

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

228-236

1 reference

17 December 2017

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

Elevated liver enzymes following initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01211.X

10.1111/J.1365-2516.2006.01211.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

16643206

1 reference

17 December 2017